Tough Decisions on Osteoporosis Drugs
Amgen (AMGN) and Eli Lilly (LLY) have endured some tough news in recent days on their experimental osteoporosis drugs. The companies' reactions provide investors with a clear picture of how pharmaceutical firms are adjusting their approaches to research and development in the face of a tougher, more safety-conscious Food & Drug Administration.
To continue reading this article you must be a Bloomberg Professional Service Subscriber.
If you believe that you may have received this message in error please let us know.